A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates.

ABSTRACT: Zika Virus (ZIKV), a virus with no severe clinical symptoms or sequelae previously associated with human infection, became a public health threat following an epidemic in French Polynesia 2013-2014 that resulted in neurological complications associated with infection. Although no treatment currently exists, several vaccines using different platforms are in clinical development. These include nucleic acid vaccines based on the prM-E protein from the virus and purified formalin-inactivated ZIKV vaccines (ZPIV) which are in Phase 1/2 clinical trials. Using a recombinant subunit platform consisting of antigens produced in Drosophila melanogaster S2 cells, we have previously shown seroconversion and protection against viremia in an immunocompetent mouse model. Here we demonstrate the eff

SUBMITTER: Medina LO 

PROVIDER: S-EPMC6236113 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature